Literature DB >> 2912911

Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13.

S C Kaufman1, F L Ferris, D G Seigel, M D Davis, D L DeMets.   

Abstract

Six risk factors for severe visual loss despite panretinal (scatter) photocoagulation were identified by analyzing data collected during the first 5 years after randomization in the Diabetic Retinopathy Study. Proportional hazards regression revealed NVD (neovascularization on/around the optic disc) to be the most important risk factor. The risk of severe visual loss rose with increasing NVD, hemorrhages/microaneurysms, retinal elevation, proteinuria, and hyperglycemia and fell with increasing "treatment density." These results are similar to previous DRS findings on untreated eyes. The importance of "treatment density" as an independent predictor of visual outcome is a new finding and lends support to the common clinical practice of repeating photocoagulation if initial treatment does not reduce or stabilize retinal neovascularization.

Entities:  

Mesh:

Year:  1989        PMID: 2912911

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.

Authors:  M M K Muqit; G R Marcellino; D B Henson; L B Young; G S Turner; P E Stanga
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

Review 2.  Laser photocoagulation for proliferative diabetic retinopathy.

Authors:  Jennifer R Evans; Manuele Michelessi; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

3.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31

4.  Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation.

Authors:  Guy Kleinmann; David Hauser; Edna Schechtman; Gennady Landa; Amir Bukelman; Ayala Pollack
Journal:  Int Ophthalmol       Date:  2007-07-10       Impact factor: 2.031

5.  Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy.

Authors:  Wen Hua; Sijia Cao; Jing Cui; David Maberley; Joanne Matsubara
Journal:  Can J Ophthalmol       Date:  2013-04       Impact factor: 1.882

Review 6.  Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review.

Authors:  A Ilarde; M Tuck
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

7.  Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

Authors:  J Fernando Arevalo; Juan G Sanchez; Andres F Lasave; Lihteh Wu; Mauricio Maia; Sergio Bonafonte; Miguel Brito; Arturo A Alezzandrini; Natalia Restrepo; Maria H Berrocal; Mario Saravia; Michel Eid Farah; Jans Fromow-Guerra; Virgilio Morales-Canton
Journal:  J Ophthalmol       Date:  2011-03-30       Impact factor: 1.909

8.  Visually evoked potentials after panretinal photocoagulation in omani patients with uncontrolled diabetes mellitus.

Authors:  Radha Shenoy; Habiba Al-Belushi; Sadiqa Al-Ajmi; Susan Margaret Al-Nabhani; Shyam Sunder Ganguly; Alexander A Bialasiewicz
Journal:  Middle East Afr J Ophthalmol       Date:  2008-04

Review 9.  Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy.

Authors:  J Fernando Arevalo
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

10.  Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series.

Authors:  Carlos Gustavo Vasconcelos de Moraes; Antonio Carlos Facio; José Humberto Costa; Roberto Freire Santiago Malta
Journal:  J Ocul Biol Dis Infor       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.